Novel insights into the regulation of cellular catabolic metabolism in macrophages through nuclear receptors. Issue 20 (4th September 2022)

• Record Type: Journal Article
• Authors: Stifel, Ulrich; Caratti, Giorgio; Tuckermann, Jan
• Is Part Of: FEBS letters. Volume 596:Issue 20(2022)
• Page Start: 2617
• Page End: 2629
• Publication Date: 2022-09-04
• Subjects: cellular metabolism -- GR -- immunometabolism -- inflammation -- LXR -- macrophages -- nuclear receptors -- PPAR -- VDR; Biochemistry -- Periodicals; Biophysics -- Periodicals; Molecular biology -- Periodicals; Biochimie -- Périodiques; Biochemistry; Biophysics; Molecular biology; Periodicals; 572.05
• DOI: 10.1002/1873-3468.14474
• Languages: English
• ISSNs: 0014-5793

Abstract

Abstract : Regulation of cellular catabolic metabolism in immune cells has recently become a major concept for resolution of inflammation. Nuclear receptors (NRs), including peroxisome proliferator activator receptors, 1, 25‐dihydroxyvitamin D (3) receptor, liver X receptors, glucocorticoid receptors, oestrogen‐related receptor α and nuclear receptor 4A1, have been identified as major modulators of inflammation, affecting innate immune cells, such as macrophages. Evidence emerges on how NRs regulate cellular metabolism in macrophages during inflammatory processes and contribute to the resolution of inflammation. This could have new implications for our understanding of how NRs shape immune responses and inform anti‐inflammatory drug design. This review will highlight the recent developments about NRs and their role in cellular metabolism in macrophages. Abstract : Regulation of cellular metabolism in macrophages has become a major concept for the resolution of inflammation. Here, we critically review how nuclear receptors (NRs) regulate cellular metabolism in macrophages during the inflammatory process and how they contribute to its resolution. New evidence advances our understanding of how NRs shape the immune response by tuning metabolism which may reveal novel anti‐inflammatory drug targets.